Cardiatis targets Crawford V thoracoabdominal aortic aneurysms with Cardiatis C5 second generation multilayer flow modulating endograft


Cardiatis announced plans of targeting Crawford Extent V lesions with its second generation aortic multilayer flow diversion device, the Cardiatis C5.

The Cardiatis C5, which obtained CE mark approval earlier this year, is specially designed for the endovascular treatment of thoracoabdominal aortic aneurysms that contain vital arterial branches. Extent V thoracoabdominal aortic aneurysms usually extend from the distal thoracic aorta to include the celiac and superior mesenteric origins. The current treatment option for patients with aneurysms in this aortic anatomy is open surgical repair which carries a relatively high risk of mortality, paralysis and renal failure.

Due to the presence of vital arterial branches, Extent V Thoracoabdominal aneurysms are currently an endovascular no-man’s land inaccessible to endovascular treatment with traditional covered aortic stent grafts. Since the Cardiatis C5 relies on next generation hemodynamic flow modulation technology it offers a credible endovascular option to patients with this debilitating disease.

“Cardiatis C5 is a next generation aortic multilayer flow modulator designed based on our paradigm-shifting multilayer flow modulation technology and feedback we collected from leading cardiothoracic surgeons,” says Noureddine Frid, chairman and chief executive officer. “The Cardiatis C5 remodels the parent artery, diverts flow away from the aneurysm wall and allows the endothelial tissue lining of the artery to regenerate; actions that reduce the probability of aneurysm rupture,” he continues.

The Cardiatis C5 exhibits a unique three-dimensional design and comes with up to 20cm in length, 4.5cm in diameter and fits on a delivery system as thin as 18F, features that make the Cardiatis C5 an attractive clinical solution for endovascular repair of Crawford V thoracoabdominal aneurysms.

The Cardiatis C5 received CE mark approval in early 2014 with excellent clinical results. It is currently available in Europe and international markets where the CE mark is accepted and has been submitted for a fast track FDA filling.